Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease

Neurology

Volumn 50, Issue 5, 1998, Pages 1323-1326

  Verhagen Metman, L ^a   Del Dotto, P ^a   Van Den Munckhof, P ^a   Fang, J ^a   Mouradian, M M ^a   Chase, Thomas ^a,b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; LEVODOPA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DYSKINESIA; HUMAN; MOTOR DYSFUNCTION; ON OFF PHENOMENON; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0006647256     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.50.5.1323     Document Type: Article

References (24)

1. Verhagen Metman L, Locatelli ER, Bravi D, Mouradian MM, Chase TN. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology 1997;48: 369-372.
2. Chase TN, Engber TM, Mouradian MM. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. Adv Neurol 1996;69:497-501.
3. Engber TM, Papa SM, Boldry RC, Chase TN. NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport 1994;5:2586-2588.
4. Papa SM, Chase TN. Levodopa induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol 1996;39:574-578.
5. Verhagen Metman L, Blanchet PJ, Mouradian MM, Chase TN. Dextromethorphan and levodopa combination therapy in parkinsonian patients with response fluctuations. Mov Disord 1996;11:184. Abstract.
6. Blanchet PJ, Verhagen Metman L, Mouradian MM, Chase TN. Acute pharmacologic blockade of dyskinesias in Parkinson's disease. Mov Disord 1996;11:580-581.
7. Kornhuber J, Bormann J, Hubers M, Rusche K, Riederer P. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human post-mortem brain study. Eur J Pharmacol 1991;206:297-300.
8. Kornhuber J, Quack G, Danysz W, et al. Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology 1995;34:713-721.
9. Kurlan R, Rothfield AB, Woodward WR, et al. Erratic gastric emptying of levodopa may cause "random" fluctuations of parkinsonian mobility. Neurology 1988;38:418-421.
10. Danysz W, Gossel M, Zajaczkowski W, Dill D, Quack G. Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats? Case of amantadine and memantine. J Neural Transm Park Dis Dement Sect 1994;7: 155-166.
11. Fleiss JL. The measurement of interrater agreement. In: Fleiss JL, ed. Statistical methods for rates and proportions. New York: Wiley and Sons, 1981:212-236.
12. Rajput AH, Uitti RJ, Lang AE, Rajput AH. Amantadine ameliorates levodopa induced dyskinesia. Neurology 1997;48:328. Abstract.
13. Adler C, Stern MB, Hurtig HI. Amantadine in advanced Parkinson's disease: good use of an old drug. J Neurol 1997;244: 336-337.
14. Freudenreich O, McEvoy JP. Added, amantadine may diminish tardive dyskinesia in patients requiring continued neuroleptics. J Clin Psychiatry 1995;56:173. Letter.
15. Silver H, Geraisy N, Schwartz M. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients. J Clin Psychiatry 1995;56:167-170.
16. Shannon KM, Goetz CG, Carroll VS, Tanner CM, Klawans HL. Amantadine and motor fluctuations in chronic Parkinson's disease. Clin Neuropharmacol 1987;10:522-526.
17. Von Voigtlander PF, Moore KE. Dopamine: release from the brain in vivo by amantadine. Science 1971;174:408-410.
18. Bailey EV, Stone TW. The mechanism of action of amantadine in parkinsonism: a review. Arch Int Pharmacodyn Ther 1975; 216:246-262.
19. Quack G, Hesselink M, Danysz W, Spanagel R. Microdialysis studies with amantadine and memantine on pharmacokinetics and effects on dopamine turnover. J Neural Transm Suppl 1995;46:97-105.
20. Nastuk WL, Su P, Doubilet P. Anticholinergic and membrane activities of amantadine in neuromuscular transmission. Nature 1976;264:76-79.
21. Hauser RA, Olanow CW. Orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with Parkinson's disease. Mov Disord 1993;8:512-514.
22. Kornhuber J, Weller M, Schoppmeyer K, Riederer P. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl 1994;43: 91-104.
23. Kornhuber J, Schoppmeyer K, Riederer P. Affinity of 1-aminoadamantanes for the sigma binding site in post-mortem human frontal cortex. Neurosci Lett 1993;163:129-131.
24. Debonnel G, de Montigny C. Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders. Life Sci 1996;58:721-734.